177Lu-NYM032 not checked

Norroy Bioscience Co., LTD

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Administered intravenously once every 6 weeks (1 cycle) for a maximum of 6 cycles.”In the company’s words, NCT07795268 on ClinicalTrials.gov
Tested for
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Main trialPhase 3
“The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.”In the company’s words, NCT07795268 on ClinicalTrials.gov

Other drugs for Prostate Cancer

All 194 drugs for Prostate Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 30 Nov 2028 Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1/2Active, not recruiting 30 Jun 2025 A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow 177Lu-NYM032

Following is part of Solo: you see every change to 177Lu-NYM032 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in